Gilead

Gilead built its reputation on HIV and hepatitis C virology, and that history still defines how the market reads a Gilead resume: deep antiviral chemistry, long-term disease-area ownership, and experience running commercial franchises that persist for a decade or more. Its Kite and CymaBay acquisitions have pushed the company further into cell therapy and liver disease, adding oncology manufacturing and biologics talent to its bench.

Recruits Lab sees the strongest external demand for Gilead alumni in virology clinical development and in cell therapy manufacturing, where Kite's commercial CAR-T experience is genuinely scarce across the industry.

Gilead's R&D organization separates Research, Clinical Development, and Regulatory Affairs, with virology and oncology run as largely distinct therapeutic-area units. Titles to know: Director and Senior Director of Clinical Development within a therapeutic area, Executive Director of Regulatory Affairs handling global filings, and, through Kite, Director of Cell Therapy Manufacturing and Vice President of Cell Therapy Technical Operations.

Commercially, Gilead's HIV franchise has produced a deep bench of Directors of Marketing and Market Access who managed multi-billion-dollar product lines, a rare skill set outside a handful of large pharma companies.

Gilead's loops typically run a recruiter screen, hiring manager interview, and a panel presentation, with virology and cell therapy roles adding a technical deep-dive on mechanism of action and manufacturing process knowledge. Commercial roles emphasize franchise P&L thinking, asking candidates to walk through pricing and access strategy for a hypothetical launch.

Cell therapy manufacturing interviews, inherited largely from the Kite integration, are notably operational: candidates are asked to troubleshoot batch failures and vein-to-vein logistics scenarios rather than answer purely theoretical questions.

The clearest big-pharma-to-biotech-startup transition here is a Kite-trained cell therapy manufacturing leader moving into a Head of Technical Operations role at an earlier-stage cell or gene therapy company. These candidates are some of the most contested in the whole biotech market because commercial CAR-T experience simply does not exist at many other companies yet.

Motivators: scientific novelty, since candidates in mature virology franchises sometimes seek modality diversity or earlier-stage science. Blockers: Gilead pays well at the director-and-above level and retains cell therapy specialists with retention grants tied to Kite integration milestones.

Gilead's Foster City headquarters is largely on-site for lab and manufacturing roles, so remote flexibility is a real differentiator when recruiting away. Counter-offers for cell therapy manufacturing talent are aggressive given how scarce that experience is; expect Gilead to move quickly with both comp and scope adjustments when it senses a flight risk.